Orlando, FL – (December 11, 2006) -- Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in ...
BOSTON (Reuters) - Two major studies of Celgene Corp's multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem cell transplantation it reduced the risk of disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback